Trend
DailyDowntrend (confirmed)
4 hourSymmetric Triangle
1 hourStrong Bullish
15 minBullish
5 minBullish
Daily trend turns up above $59.51
Key levels
Resistance$63.57
Resistance$59.51
Support$57.00
Support$54.85
Latest news & SEC filings
AnalystMorgan Stanley keeps Overweight rating on BioMarin Pharmaceutical, cuts price target to $103
AnalystB. Riley trims BioMarin outlook, cuts target to $27 while keeping Buy
AnalystMorgan Stanley keeps Buy rating on BioMarin Pharmaceutical, cuts price target
ProductBioMarin files regulatory submissions for vosoritida in hypochondroplasia
All BMRN news →BioMarin is a biotechnology company that develops and sells medicines for rare, genetically defined diseases. Its products include treatments for achondroplasia, enzyme therapies for lysosomal storage disorders such as MPS I, IVA and VI, and therapies for phenylketonuria and CLN2 disease. The company also has clinical programs in growth disorders and other genetic conditions. It sells across North America, Europe and Asia, and manufactures its products at facilities in California and Ireland.
Based on the company's 10-K filed Feb 26, 2026.
Nasdaq · Healthcare
SEPT Low Target
$55.00
SEPT Mid Target
$86.00
SEPT High Target
$119.00
Analyst Consensus
$86.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for BMRN.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
P/E Forward, P/B, Analyst Consensus
Fair Value
$82.22
31
Moat Score
NONE
4/9
Piotroski Score
5.7
Altman Z-Score
Insider Signal
NEUTRAL
0 buys / 1 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Friberg Gregory R | officer | Sale | 4,086 | $245K | Sep 30, 2026 |
| Countouriotis Athena | director | Buy | 7,490 | - | Jun 2, 2026 |
| Walbert Timothy P | director | Buy | 7,490 | - | Jun 2, 2026 |
| Ho Maykin | director | Buy | 7,490 | - | Jun 2, 2026 |
| HOMBACH ROBERT J. | director | Buy | 7,490 | - | Jun 2, 2026 |
| Enyedy Mark J | director | Buy | 7,490 | - | Jun 2, 2026 |
| Dere Willard H | director | Buy | 7,490 | - | Jun 2, 2026 |
| CLARK IAN T | director | Buy | 7,490 | - | Jun 2, 2026 |
| Bodem Barbara W. | director | Buy | 7,490 | - | Jun 2, 2026 |
| ANDERSON ELIZABETH M | director | Buy | 7,490 | - | Jun 2, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
12.9%
3yr Revenue CAGR
15.4%
EPS Growth YoY
-18.55%
FCF Growth YoY
48.7%
Revenue Trend
STRONG
SEPT Investing tracks real-time dark pool institutional trades for BMRN, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 16:29:19 | $56.73 | 1,000 | $$57K | SELL |
| 16:22:15 | $56.82 | 1,800 | $$102K | MIDPOINT |
| 16:22:15 | $56.82 | 2,370 | $$135K | MIDPOINT |
| 16:18:40 | $56.87 | 1,048 | $$60K | SELL |
| 16:16:22 | $56.86 | 1,652 | $$94K | SELL |
5 dark pool trades shown · $$447K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT Investing provides real-time options flow tracking for BMRN, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $62.5 | Nov 20 | 7 | $$2300 | 230 | BLOCK |
| CALL | $57.5 | Nov 20 | 7 | $$20.7K | 230 | BLOCK |
2 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for BIOMARIN PHARMACEUTICAL INC (BMRN) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (8 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →BIOMARIN PHARMACEUTICAL INC (BMRN) is at $57.05, up 0.63% (+$0.35) at the Nov 13, 2026 close.
Latest BMRN news — Nov 13, 2026: Morgan Stanley keeps Overweight rating on BioMarin Pharmaceutical, cuts price target to $103 · Nov 13, 2026: B. Riley trims BioMarin outlook, cuts target to $27 while keeping Buy
The average analyst price target for BMRN is $86.00, ranging from $55 to $119, based on 15 analysts. Latest: JP Morgan maintains on Nov 4, 2026.
Analyst ratings for BMRN: 0 Buy, 25 Hold, 0 Sell — consensus Hold.
BMRN last reported on Nov 2, 2026: EPS $0.23 vs -$0.08 expected — a beat of 376.1%.
BMRN trades at a P/E of 142.7 vs a Healthcare average of 17.7.
BMRN does not currently pay a dividend.
BIOMARIN PHARMACEUTICAL INC reported $4.2B of debt and $874M of cash (Jun 30, 2026).
Support: $57.00, $54.85, $52.00. Resistance: $59.51, $63.57, $66.88.
Insider activity: NEUTRAL, 0 buys and 1 sells in the last 90 days.
Nov 13, 2026: Morgan Stanley keeps Overweight rating on BioMarin Pharmaceutical, cuts price target to $103 · Nov 13, 2026: B. Riley trims BioMarin outlook, cuts target to $27 while keeping Buy · Nov 13, 2026: Morgan Stanley keeps Buy rating on BioMarin Pharmaceutical, cuts price target